Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Inhibikase Therapeutics

31/03/2023 22:01

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
December. The lone analyst forecast for the quarter was for a
loss of 19 cents per share.
    * Revenue rose 3,147.4% to $63.00 thousand from a year ago;
analysts expected zero. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had risen by 35.9% this
quarter.
    * The company reported a quarterly loss of $4.17 million.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 31 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.19          -0.18          Beat
 Sep. 30 2022      -0.18          -0.18          Met
 Jun. 30 2022      -0.19          -0.18          Beat
 Mar. 31 2022      -0.17          -0.18          Missed